Whereas arginine vasopressin binds to its receptor subtypes V 1 R and V 2 R with equal affinity of approximately 2 nM, nonpeptide antagonists interact differently with vasopressin receptor subtypes. The V 2 R antagonist binding site was mapped by site-directed mutagenesis at six selected amino acid positions, K100D, A110W, M120V, L175Y, R202S, and F307I, predicted to be involved in antagonist binding differences between V 2 R and V 1 R. These mutations did not alter the affinity for arginine vasopressin. However, the affinity for six nonpeptide receptor
chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-o-tolu-m-toluidide], and OPC31260, [(Ϯ)-5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-1,2, 3,4,5-tetrahydro-1H-benzazepine monohydrochloride], was altered to varying degrees, resulting in differences up to 6000-fold. Replacement of the small alanine for the bulky tryptophan in position 110 resulted in a reduced affinity for all six antagonists. In contrast, replacement of the large methionine for the smaller valine in position 120 caused a dramatic increase in affinity, up to a K i of 7 fM for OPC31260. Molecular modeling revealed that the binding sites for arginine vasopressin and the nonpeptide antagonists are partially overlapping. Whereas arginine vasopressin binds on the extracellular surface of V 2 R, the nonpeptide antagonists penetrate deeper into the transmembrane region of the receptor, in particular OPC21268. The mutagenesis data point to significant differences in the shape of the V 1 R and V 2 R antagonist binding pockets. The most important factor determining the specificity of nonpeptide antagonists seems to be the shape of the binding pocket on the receptor.
Arginine vasopressin (AVP), the antidiuretic hormone, is a cyclic nonapeptide that modulates various physiological functions, such as water reabsorption, blood volume, blood pressure, cellular proliferation, and adrenocorticotropic hormone secretion (Thibonnier et al., 1998 (Thibonnier et al., , 2001 . The antidiuretic effect of AVP is mediated by the vasopressin V 2 receptor (V 2 R), a member of the large family of G protein-coupled receptors (Robben et al., 2004) . V 2 R is a 41-kDa seven-transmembrane protein of 371 residues (Birnbaumer et al., 1992) . V 2 R is expressed in the basolateral membrane of epithelial cells of the renal distal tubule and the collecting ducts (Hermosilla et al., 2004; Robben et al., 2004) . In the collecting duct of the kidney, AVP binds to the V 2 R, thereby activating the G s /adenylyl cyclase system. The subsequent rise in intracellular cAMP levels induces protein kinase A to phosphorylate, among other proteins, the human water-channel aquaporin-2, which relocates from the intracellular vesicles to the apical membrane, resulting in free water reabsorption and urine concentration (Robben et al., 2004) .
Specific mutations in V 2 R cause loss of function or dysregulation of V 2 R in patients with X-linked congenital nephrogenic diabetes insipidus (NDI) (Morello and Bichet, 2001; Robben et al., 2004) . Patients suffering from NDI are unable to concentrate urine despite elevated circulating levels of AVP (Wenkert et al., 1996) . To date, more than 150 distinct NDI-causing mutations within the V 2 R gene structure have been described. In some instances, the functional consequences of the mutation are easily understood because of the presence of premature stop codons or frameshifts, leading to severely truncated or altered nonfunctional receptor proteins. Up to 70% of these mutations result in transportdefective receptors that fail to reach the cellular membrane surface (Morello et al., 2000b; Hermosilla et al., 2004) .
The AVP/oxytocin receptor family represents a suitable system to investigate structure-function relationships of receptor subtypes. Pharmacological and molecular cloning studies of the V 1 , V 2 , and V 3 AVP receptors, as well as the related oxytocin receptor, have shown that these peptide receptors display a great diversity in their functional properties despite high sequence homology. These receptors can bind not only the native hormone AVP but also potent and selective cyclic and linear peptide analogs, as well as nonpeptide antagonists (Cotte et al., 1998) . Mutagenesis studies have indicated that the ligand-binding pocket includes residues located on the extracellular loops as well as in adjoining transmembrane helices of the receptors (Oksche et al., 2002) .
In this work, we set out to determine key residues responsible for the differential nonpeptide ligand binding specificity to V 2 R versus V 1 R. Six nonconservative single amino acid differences between the V 2 R and the V 1 R sequences (K100D, A110W, M120V, L175Y, R202S, and F307I) were selected for this investigation because of their location within the putative ligand binding pocket. The amino acid in position 202 is particularly interesting, because an R202C mutation has been identified in patients suffering from NDI (Morello and Bichet, 2001) . Dissociation constants of the six nonpeptide receptor antagonists for each mutant V 2 R were determined. The data were interpreted by molecular modeling of antagonist docking to wild-type and mutant receptors. The results point to differences between the V 1 R and V 2 R antagonist binding sites. The most important factor in determining the ]Vasopressin was obtained from Bachem (Bubendorf, Switzerland). OPC31260, OPC21268, and OPC41061 were kindly provided by Otsuka Pharmaceutical, Inc. (Tokyo, Japan). SR121463B, SR49059, and SSR149415 were kindly provided by sanofi-synthelabo (Toulouse, France).
Materials and Methods

Chemicals
Construction of Receptor Expression Plasmids
Wild-Type V 2 R-GFP. The human V 2 R cDNA (comprising the coding region, nucleotides 219-1354 of the human cDNA sequence, GenBank accession number 4895106) was isolated from pcDNA plasmid by XbaI/BamHI digest and subcloned into the XbaI/BamHI-cut pEGFP-N1 plasmid (BD Biosciences Clontech, Palo Alto, CA) for comparative expression analysis.
Mutant V 2 R-GFP. Plasmids encoding mutants K100D, A110W, M120V, L175Y, R202S, and F307I were generated with the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) following manufacturer's instructions. The wild-type V 2 R-GFP plasmid was used as template. Sense and antisense primers encoding single amino acid changes were purchased from Invitrogen (Carlsbad, CA). The sequence of each construct was checked by Cleveland Genomics, Inc. (Cleveland, OH).
Cell Culture and Transfection
Chinese hamster ovary-K1 cells (American Type Culture Collection, Manassas, VA) were grown in F-12K medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen) and 500 units/ml penicillin/streptomycin (Invitrogen) in an atmosphere of 95% air and 5% CO 2 at 37°C. Stable transfection was done using the Lipofectamine 2000 transfection kit (Invitrogen) following the manufacturer's instructions. The stable cell lines of wild type and mutants were selected by flow-cytometry sorting (Cancer Center Core Facility, Case Western Reserve University) and G418 (Invitrogen) selection up to 8 or 12 g/ml.
Radioligand Binding Assays
The binding of [ 3 H]AVP to intact Chinese hamster ovary cells was performed as described previously (Thibonnier et al., 2000) . In brief, the cells were seeded at a density of 1.75 ϫ 10 5 /well in 12-well plates. Twenty-four hours after plating, the cells were washed twice with binding buffer (10 mM MgCl 2 , 0.2% bovine serum albumin in 1ϫ Dulbecco's phosphate-buffered saline, pH 7.4). For saturation binding analysis, the cells were then incubated with increasing concentrations of [ 3 H]AVP diluted in the same buffer in the presence (nonspecific binding) or absence (total binding) of 100 nM unlabeled AVP for 30 min at 30°C in a shaking water bath. For competition binding analysis, cells were incubated with 2 nM [ 3 H]AVP in the presence of increasing concentrations of unlabeled AVP or nonpeptide antagonist for 30 min at 30°C in a shaking water bath. After washing three times with ice-cold phosphate-buffered saline, the cells were lysed with 0.1 N NaOH and 0.1% SDS. The lysates were then transferred to scintillation vials, and 4 ml of ReadyProtein (Beckman Coulter, Inc., Fullerton, CA) scintillation cocktail was added. Radioactivity was determined in a liquid scintillation counter (LS6000; Beckman Coulter). K d and inhibition constant (K i ) values Nitrogen is blue, oxygen is red, and sulfur is orange, and carbon is magenta on the ligand, yellow on the mutated side chains, and green on the rest of the receptor. The amino acid one-letter code of AVP and V 2 R residues is in lowercase and uppercase, respectively. This figure was generated with program PyMOL.
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were calculated using standard equations and program Prism 4.0 (GraphPad Software, Inc., San Diego, CA) (Thibonnier et al., 2000) .
Molecular Modeling
A molecular model of V 2 R was built based upon a model of V 1 R, previously established in this laboratory (Thibonnier et al., 2000) . Program O was used to visualize the amino acid replacement models (Jones et al., 1991) . Energy minimization was carried out with program CNS (Brunger et al., 1998) .
Docking of AVP and Antagonists to the V 2 R Model
Docking of AVP and antagonists was carried out with the program LIGIN (Sobolev et al., 1996) . The docking was done for each compound and for each chimeric receptor separately followed by energy minimization with program CNS. Ligand-receptor distances were calculated with the program CONTACT within the CCP4 suite of crystallographic programs (Collaborative Computational Project, Number 4, 1994) .
Results
Selection of Point Mutants. Previous studies have localized the binding site for AVP and its antagonists in a region delineated by the extracellular loops and the adjoining transmembrane regions of the V 2 R (Thibonnier et al., 2002) . To further map the binding site and to identify residues responsible for the specificity of antagonists binding to V 1 and V 2 receptor subtypes, point mutations were created by introducing into the V 2 R sequence the corresponding residues from the V 1 R sequence. The degree of sequence identity between V 2 R and V 1 R is 65, 44, and 21% for the extracellular loops el1, el2, and el3, respectively. The overall degree of sequence identity is 41%, high enough to assume that the overall fold of these two receptors is conserved. Because there are many sequence differences, we wanted to select mutations that potentially affect antagonist specificity. Twenty point mutations were initially selected within the putative ligand-binding region based on the nonconservative nature of the amino acid replacements. The number of point mutants employed in this study was eventually reduced to the following six-well expressed mutants: K100D, A110W, M120V, L175Y, R202S, and F307I. The criteria for selecting these mutations include charge reversal (K100D), large changes in the volume of the side chain (A110W, M120V, and R202S), and replacements of aliphatic to aromatic side chains or vice versa (L175Y and F307I). The location of these mutations in V 2 R is shown in Fig. 1 . Mutations K100D, A110W, R202S, and F307I are depicted on extracellular loops, whereas mutations M120V and L175Y are shown in transmembrane helices. However, there is some degree of uncertainty in assigning the boundaries between transmembrane regions and loops. For example, residue Phe-307 has been reported to be on transmembrane helix 7 (Mouillac et al., 1995) .
Affinity of AVP for the V 2 R Mutants. The affinity of AVP for the wild-type V 2 R, as determined by saturation binding experiments with [
3 H]AVP, is 2.2 nM (Fig. 2) , identical to the value we reported previously (see Table 1 ) (Thibonnier et al., 2001 ). None of the six point mutations affected AVP affinity for the V 2 R in any significant way. In silico docking of AVP to V 2 R explains these findings for each of the receptor mutant. Four of the six mutated V 2 R residues make contact with AVP, namely Lys-100, Met-120, Leu-175, and Phe-307 (Fig. 3) . Mutations at these positions do not affect the affinity, apparently for the following reasons. Residue 100 makes only backbone contacts with AVP; therefore, replacement of the side chain should has no effect on binding AVP. Mutations in the remaining three positions do not seem to alter interactions with AVP. Methionine and valine at jpet.aspetjournals.org position 120 both exhibit hydrophobic contacts with f3 and q4 of AVP. Leucine and tyrosine at position 175 both make hydrophobic contacts with backbone atoms of q4 and n5 of AVP. Phenylalanine and isoleucine at position 307 both make hydrophobic contacts with the AVP-disulfide bridge between c1 and c6 of AVP. The docking results provide an explanation for the lack of any significant effect of these amino acid replacements from V 2 R to the corresponding residues in V 1 R on the affinity for AVP. The concept of nonpeptide antagonists acting as molecular chaperones to restore agonist binding (Morello et al., 2000a) does not apply to these mutants as they all bind AVP with the same affinity as wild-type V 2 R. However, these mutations greatly affect binding of nonpeptide antagonists.
Affinity of the Six Nonpeptide Antagonists for the V 2 R Mutants. Figure 4 shows the chemical structure of the six nonpeptide antagonists used in this study. There is only partial overlap between the receptor binding sites of the , and el3 for the extracellular loops and il1, il2, and il3 for the intracellular loops. The binding sites for agonist and antagonist are distinct with partial overlap. This figure was generated with programs MOLSCRIPT (Esnouf, 1999) and RASTER3D (Merritt and Murphy, 1994) . 568 antagonists and AVP. As shown in Fig. 5 , at variance with AVP, the antagonists penetrate deeper into the transmembrane region of the receptor, in particular OPC21268. Docking onto V 2 R reveals that all six mutated residues are involved in binding nonpeptide antagonists. However, not all of the six residues are in contact with any given specific antagonist (Table 2) .
Modeling of the Antagonists Binding to the V 2 R. The results of the [ 3 H]AVP/antagonist competition binding experiments with the six selected nonpeptide antagonists and the six V 2 R/V 1 R mutants are shown in Fig. 6 , and the K i values are summarized in Table 3 .
Antagonist Binding to the K100D Mutant. Large differences in the affinity of this mutant are confined to SR49059 (14-fold weaker affinity) and OPC41061 (6-fold stronger affinity). Interestingly, docking followed by energy refinement did not show any direct involvement of residue 100 in the binding of these two compounds. It is possible that the K100D mutation causes a conformational change, which indirectly affects the binding of SR49059 and OPC41061.
Antagonist Binding to the A110W Mutant. A110W is the only mutation that dramatically weakens the binding of all six nonpeptide antagonists, particularly for SSR14915 and OPC21268. For these two antagonists, no binding at all could be detected. A likely explanation for the decrease in affinity is overcrowding due to the introduction of the bulky tryptophan in place of the small alanine side chain. To relieve steric strain, the nearby Leu-175 has to adopt a different conformation, which probably results in a loss of hydrophobic interactions of this residue with antagonists (Fig. 7) . Tryptophan in position 110 may also affect the nearby Arg-202, which interacts with some of the antagonists. The decrease in affinity ranges from 42-fold for SR121463B to 1340-fold for OPC41061. The binding of all nonpeptide antagonists to this mutant is also weaker than the binding of AVP by a factor up to ϳ200-fold.
Antagonist Binding to the M120V Mutant. This mutant exhibits the most dramatic improvement of the affinity of all six nonpeptide antagonists, with a 500-to 6000-fold decrease in K i values. In general, the OPC compounds are more tightly bound than the SR compounds. For instance, the affinity of OPC31260 for the M120V mutant V 2 R is very high, with a K i of only 7 fM. The reason for this amazing increase in affinity is probably because of relief of overcrowding by the smaller valine compared with the more bulky methionine. This introduces more flexibility into the system, which provides for an improved fit of the ligand to the receptor. Thus, it seems that entropic contributions to the binding free energy are very important in this case. However, enthalpy changes must also be favorable, because increased flexibility allows for better interactions between aromatic moieties of the ligand and the receptor (Fig. 7) . This effect is more pronounced for the OPC compounds, which generally have more aromatic moieties than the SR compounds.
Antagonist Binding to the L175Y Mutant. Although unlabeled AVP could displace [ 3 H]AVP from this mutated receptor, all six nonpeptide antagonists prevented the binding of [ 3 H]AVP, even at antagonist concentration as low as femtomolar. The most likely explanation is that antagonist binding is so tight that AVP cannot displace it. The increased affinity may be due to hydrogen bonds of the tyrosine hydroxyl group as well as -stacking of the tyrosine ring with the aromatic moieties of the compounds.
Antagonist Binding to the R202S Mutant. This mutation has distinct effects on the binding characteristics of one jpet.aspetjournals.org SR and one OPC compound. There is no change in the affinity for OPC41061, whereas there is a 10-fold increase in the affinity for SR121463B. Docking of OPC41061 suggests that this antagonist makes no interactions with residue 202, whether it is an arginine or a serine. In contrast, docking of SR121463B suggests short contacts of this antagonist with the guanido group of Arg-202. Substitution of the large arginine for the smaller serine improves binding, apparently because of relief of overcrowding.
Antagonist Binding to the F307I Mutant. Phe-307 makes a very important contribution to the binding of the antagonists, because modeling suggests that this residue is involved in binding all six nonpeptide antagonists ( Table 2) . The mutation to isoleucine at this position increases the affinity for all six nonpeptide antagonists by a factor of ranging from 10-fold for SR49059 to 375-fold for OPC41061. This phenomenon might be a consequence of the environment of residue 307, which is aliphatic in character. An isoleucine at this position can make better hydrophobic interactions with neighboring Leu-302 and Met-311. The latter residue is involved in binding OPC41061, according to modeling. Thus, an isoleucine at position 307 seems to position the receptor better for binding to the antagonists.
Discussion
Our findings suggest that AVP and the nonpeptide antagonists fit tightly into the binding pocket of the V 2 R. Docking indicates an overall binding pocket of dimensions 25 ϫ 20 ϫ 15 Å, with the first dimension parallel to the surface of the membrane (Fig. 8) . AVP binds to a subpocket of size 22 ϫ 14 ϫ 14Å. The nonpeptide antagonists occupy a subpocket of dimensions 12 ϫ 20 ϫ 10 Å. The investigated mutations affect only the subpocket for nonpeptide antagonists. Narrowing of this ligand-binding subpocket with the A110W mutation interferes with binding. In contrast, widening of the pocket by the M120V and the F307I mutations improves antagonist binding. These results point to a significant difference in the shape of the nonpeptide antagonist binding pocket between V 1 R and V 2 R. In V 1 R, the single small-tolarge mutation investigated in this work, A110W, is apparently compensated by three large-to-small mutations, K100D, M120V, and R202S. None of the single point mutants by themselves is responsible for nonpeptide antagonist specificity toward a particular receptor subtype. Rather, the cu- Fig. 7 . Mutagenesis of the small alanine at position 110 for the bulky tryptophan introduces overcrowding and narrows the binding site. To alleviate overcrowding, Leu-175 may readjust to a position where it no longer can interact with the antagonist. This figure was generated with programs MOLSCRIPT (Esnouf, 1999) and RASTER3D (Merritt and Murphy, 1994) . mulative effect of multiple mutations seems to determine receptor subtype specificity. These findings may help design more potent and selective nonpeptide AVP receptor antagonists.
